ET-19 A PHASE 1 STUDY EVALUATING ABT-414 WITH TEMOZOLOMIDE (TMZ) OR CONCURRENT RADIOTHERAPY (RT) AND TMZ IN GLIOBLASTOMA (GBM)

BACKGROUND: Standard therapies have little effect on the poor survival rates of GBM. Abnormal epidermal growth factor receptor (EGFR) expression and signaling are common in GBM. ABT-414 is a unique antibody-drug conjugate, with a toxic payload (MMAF) targeted to active EGFR or mutant EGFRvIII, that...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Gan, Hui K., Fichtel, Lisa, Lassman, Andrew B., Merrell, Ryan, van den Bent, Martin, Kumthekar, Priya, Scott, Andrew M., Pedersen, Michelle, Gomez, Erica, Fischer, JuDee, Ames, William, Xiong, Hao, Dudley, Matt, Munasinghe, Wijith, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle, Reardon, David A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2014
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4218114/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou255.19
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge